Targeted ablative therapies for prostate cancer

Jared S. Winoker, Harry Anastos, Ardeshir R. Rastinehad

Research output: Chapter in Book/Report/Conference proceedingChapter


Men diagnosed with low- to intermediate-risk, clinically localized prostate cancer (PCa) often face a daunting and difficult decision with respect to treatment: active surveillance (AS) or radical therapy. This decision is further confounded by the fact that many of these men diagnosed, by an elevated PSA, will have indolent disease and never require intervention. Radical treatments, including radical prostatectomy and whole-gland radiation, offer greater certainty for cancer control, but at the risk of significant urinary and/or sexual morbidity. Conversely, AS preserves genitourinary function and quality of life in exchange for burdensome surveillance and the psychological impact of living with cancer.

Original languageEnglish (US)
Title of host publicationCancer Treatment and Research
PublisherSpringer International Publishing
Number of pages39
StatePublished - 2018
Externally publishedYes

Publication series

NameCancer Treatment and Research
ISSN (Print)0927-3042


  • Biochemical recurrence
  • Electroporation
  • Focal therapy
  • High-intensity focused ultrasound
  • Photodynamic therapy
  • Prostate cancer treatment
  • Radiofrequency ablation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Targeted ablative therapies for prostate cancer'. Together they form a unique fingerprint.

Cite this